Skip to main content

Table 4 Frequency of adverse events reported during the therapeutic efficacy monitoring in Uganda at all sites, 2018–2019

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

  Artemether-lumefantrine, n (%) Dihydroartemisinin-piperaquine, n (%)
Adverse events
 Cough 119 (39.0) 122 (42.8)
 Acute watery diarrhea 43 (14.1) 33 (11.6)
 Mild skin rash 15 (4.9) 14 (4.9)
 Mild anemia (8.0–10.0 g/dl) 16 (5.2) 15 (5.3)
Serious adverse events
 Fracture 1 (0.3) 0 (0.0)
 Severe malaria 1 (0.3) 0 (0.0)